CGenetix
French tech company | Builders Republic
About
Molecular diagnostics company that helps transplant teams detect early damage to a grafted organ without a tissue biopsy — blood-based analysis of graft-derived cell-free DNA (liquid biopsy), its epigenetic markers and digital PCR, starting with kidney then lung transplantation.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2022
- Registered office
- Paris
- Region
- IDF
- Tracked rounds
- 2
- Amount raised
- 0.5 M€
Operations
- Seed · 2025
- Pre-seed · 2024
Investors
- Baltic Sandbox Ventures
- Calyseed
- Ijapaj Ventures